$ABBV

Atopic dermatitis drug market projected to grow from $8.5B (2023) to $21.5B (2033) at 9.8% CAGR, fueled by seven late-stage pipeline therapies.

Global atopic dermatitis market projected to grow from $10.8B in 2023 to $26.2B by 2033, driven by seven late-stage pipeline drugs and expanded treatment options.

Crohn's Disease drug market projected to grow 45% to $13.8B by 2032, driven by eight new therapies with novel mechanisms of action reshaping competition.

Johnson & Johnson's 63-year dividend streak and AAA rating offer security, but 2.2% yield falls short of 4% income targets, requiring complementary holdings.

Dividend Aristocrats with 25+ years of consecutive dividend increases and 3%+ yields offer inflation protection and steady income amid Fed pause.

Red Spruce Capital significantly increased its stake in the Invesco BulletShares 2028 Corporate Bond ETF, now representing 3.67% of fund assets through a deliberate fixed-income ladder strategy.

Red Spruce Capital deployed $4.03 million in Invesco's 2027 corporate bond ETF, expanding its fixed-income ladder strategy with a 4.21% portfolio allocation to secure predictable cash flows.

Red Spruce Capital increased Invesco 2029 Bond ETF holdings by $3.35M, reflecting institutional preference for defined-maturity fixed-income with predictable 4.5% yields.

AbbVie maintains 10+ years of consecutive dividend increases despite Humira patent loss, buoyed by blockbuster drugs Skyrizi and Rinvoq projected to reach $50B by 2030.

President Trump's executive order imposes 100% tariffs on imported drugs, exempting 13 companies with MFN agreements and U.S. manufacturing commitments through 2029.

Schwab's dividend ETF ($SCHD) reconstitutes holdings, replacing energy stocks with healthcare leaders. Offers 3.5% yield, triple S&P 500 average.

Tech stocks tumble toward correction as investors shift to defensive healthcare dividends. AbbVie and Amgen offer stability through economic uncertainty.

Spinal cord injury market projected to grow from $354M to $1.4B by 2034 as six emerging therapies target previously untreated condition.

Merck acquires Terns Pharmaceutical for $6.7B to expand cancer pipeline with oral BCR-ABL1 inhibitor, targeting $70B commercial opportunity by mid-2030s.

Over 120 pharmaceutical companies are developing 140+ drugs for systemic lupus erythematosus, with major players like Roche and Novartis advancing promising new treatment mechanisms.

Schwab's Dividend ETF added UnitedHealth and Abbott while removing AbbVie, boosting healthcare allocation to 18.9% and increasing average dividend growth rates.

Global bile duct cancer market projected to reach $3.89B by 2030 from $2.59B in 2025, driven by immunotherapy, AI diagnostics, and rising disease prevalence.

$ABBV and $BMY deliver above-average dividend yields and growth, standing out as rare healthcare sector exceptions for patient income investors navigating patent cliffs through innovation.

AbbVie stock down 11% YTD but trades at 14x forward P/E with 0.49 PEG, suggesting undervaluation amid strong new drug momentum and 3.4% dividend yield.

Schwab's dividend ETF ($SCHD) combines 3.1% yield with strict quality filters, averaging 12.5% annual returns over ten years through defensive sector exposure.